Our Editorial Board Members work closely with our in-house editors to ensure that all manuscripts are subject to the same editorial standards and journal policies. Editorial Board Members are active researchers recognized as experts in their field. Our Editorial Board Members handle manuscripts within their areas of expertise, overseeing all aspects of the peer review process from submission to acceptance.
Editorial Board Members
Research interests: systems pharmacology, computer-aided drug design, network biology, network medicine, personalised medicine
Dr Patrick Aloy is an ICREA Research Professor and Principal Investigator of the Structural Bioinformatics and Network Biology (SB&NB) lab at the IRB. He obtained his BSc in Biochemistry, MSc in Biotechnology and PhD in Computational Biology by the Autonomous University of Barcelona, Spain. He spent one and a half years working at the Imperial Cancer Research Fund (London, UK), and over five years as postdoctoral researcher and staff scientist at the European Molecular Biology Laboratory (Heidelberg, DE).
The main goal of his laboratory is to combine molecular, cell and computational biology to unveil the basic wiring architecture and dynamics of physio-pathological pathways to discover new therapeutic opportunities and increase our understanding of how biological systems change from the healthy state to disease. In the last years he has been developing resources to process, harmonize and integrate bioactivity data on small molecules, providing compound bioactivity descriptors that push the similarity principle beyond chemical properties, reaching various ambits of biology. Currently, the main research line in the lab is to collect genuinely heterogeneous datasets and develop novel methodologies to truly integrate different layers of regulation to unveil disease signatures. Moreover, they are convinced that artificial intelligence (AI) will transform drug discovery, as it is reshaping other areas of science and technology, and biological signatures are the key to guide the (semi) automated design of chemical compounds to globally revert disease states, beyond individual targets. Webpage.
Research interests: Inherited cancers, germline genomics, cancer genetics, PTEN-related disease genetics, cancer microbiome
Prof. Charis Eng is the inaugural Chair of the Cleveland Clinic’s Genomic Medicine Institute and inaugural Director, Center for Personalized Genetic Healthcare, an American Cancer Society Clinical Research Professor and the Sondra J. and Stephen R. Hardis Endowed Chair of Cancer Genomic Medicine at the Cleveland Clinic. She is Professor and Vice Chair, Department of Genetics and Genome Sciences, Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine. In her leadership roles, she continues to implement evidence-based genetic- and genomics-enabled precision healthcare, improving care for patients at genetic risk of disease nationally and globally. Her expertise lies in the genomics of heritable cancers, chief of which are those of the breasts and thyroid, and studies the microbiome as a transducer of the environment to the genome. With >500 peer-reviewed articles, she is an elected member of the National Academy of Medicine and was conferred the American Cancer Society Medal of Honor, among numerous awards. Prof Eng has served as advisory to DHHS Secretary’s Committee on Genetics, Health & Society and is Editor-in-Chief of Human Molecular Genetics, a Senior Editor of Cancer Research and an Associate Editor of npj Genomic Medicine. Webpage.
Research interests: transcriptomics, integrative genomics, evolutionary genetics, genetic policy
Greg Gibson has twin interests in genotype-by-environment interactions and integrative genomics for personalized medicine. His major focus is applications of transcriptomics to elucidate the mechanisms by which genetic variation mediates complex phenotypes and pathology. In parallel, since his days as a fly geneticist, he has been studying how canalization influences the evolution of traits. Recent work in single cell and bulk tissue transcriptomics has explored the use of transcriptional risk scores in inflammatory bowel disease and autoimmunity. Greg has authored two text-books of genomics and human genetics, and maintains the GenomesTake monthly genetics blog. Webpage.
Research interests: Cancer Genomics, Cancer Immunotherapy, Noncoding RNAs, Computational Biology
Dr. Leng Han is an Associate Professor at Institute of Biosciences and Technology, Texas A&M University. Our lab utilizes cutting-edge techniques in systems biology to understand the molecular mechanisms of complex diseases. We have comprehensive understanding of the molecular mechanisms of novel transcriptomic elements in cancer (Trends in Cancer, 2018), including pseudogenes (Nature Communications, 2014), lncRNA (Cancer Research, 2015), RNA editing (Cancer Cell, 2015), eQTL (Nucleic Acids Research, 2018), snoRNA (Cell Reports, 2017), APA (Journal of the National Cancer Institute, 2018), circRNA (Genome Medicine, 2019) and eRNA (Nature Communications, 2019). We pioneered a series of pan-cancer analyses to provide clinical insights into cancer therapy, including chronotherapy (Cell Systems, 2018), hypoxia-targeted therapy (Nature Metabolism, 2019), and immunotherapy (Nature Immunology, 2019; Nature Communications, 2020a; Nature Communications, 2020b; JNCI, 2021, Cancer Cell, 2021). We have been invited to contribute review, commentary and spotlight by multiple journals, including Nature Biotechnology, Nature Metabolism, Trends in Genetics, Trends in Cancer, Trends in Molecular Medicine, Genome Medicine, and Oncogene. Webpage.
Research interests: bioinformatics, systems biology, neurodegeneration, transcriptomics, spatial transcriptomics, drug repurposing
Winston Hide, Ph.D., is the Director of the Precision RNA Medicine Core at Beth Israel Deaconess Medical Center. He is an associate professor in the Department of Pathology at Harvard Medical School.
Dr. Hide applies systematic organizing approaches to genomic data to reveal critical disease events occurring in cancers and neurodegeneration. He builds and implements systems that result in discovery and prioritization of key genes, pathways, processes and prediction of drugs that can targets these in complex diseases. Dr. Hide has worked with key industry partners, including Biogen, to develop translational pipelines for target prioritization.
Dr. Hide was elected into the Academy of Science of South Africa in 2007. He was also the first recipient of the “International Society for Computational Biology Award for Outstanding Achievement,” given in recognition of his work for the development of computational biology and bioinformatics in Africa. Webpage.
Research interests: Computational biology, bioinformatics, machine learning, rare diseases
Peter is Professor of Computational Biology at The Jackson Laboratory for Genomic Medicine, Farmington, CT. Previously, Peter was Professor for Medical Genomics at the Charité Universitätsmedizin Berlin and was adjunct professor for Bioinformatics in the Department of Mathematics and Computer Science of the Free University of Berlin. Peter’s research group initially characterized Mendelian disease-associated genes including CA8 and PIGV and characterized a novel mode of pathogenesis in a mouse model of Marfan syndrome. The central research theme since 2004 has been the development of computational resources and algorithms for the study of human disease; We have developed the Human Phenotype Ontology (HPO), which provides comprehensive bioinformatic resources for the analysis of human diseases and phenotypes, offering a computational bridge between genome biology and clinical medicine. Peter’s group has developed algorithms for genomics research involving ChIP-seq, NGS-based T-Cell Receptor profiling, and RNA-seq, as well as translational research and diagnostics by whole-exome and whole-genome sequencing. Webpage.
Research interests: My scientific interests focus on precision medicine particularly pharmacogenomics & cancer, and the contribution of ADME genes to drug response and side-effect. Moreover, I am interested in the consideration of novel –omics technologies (e.g. genomics, epigenomics, metabolomics), and the implementation of research findings into clinical practice.
Matthias Schwab studied medicine followed by fellowships in Children's Medicine and Clinical Phar-macology with board certifications for both disciplines. Since 2007 he is Director of the Dept. of Clinical Pharmacology, University Hospital Tuebingen, and the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany. He participated in and/or coordinated a number of national/international research networks (e.g., EU-ITN, EU-IMIs, EU-Horizon2020, BMBF). Moreover, he is member of several committees (e.g. German National Academy of Sciences Leopoldina, German Academy of Science and Literature, Mainz), and received numerous awards (e.g. Galenus von Pergamon Award, the Robert-Pfleger Research Award). His scientific accomplishments result in > 350 peer reviewed publications, and he is repeadetly listed as Clarivate Highly Cited Reseacher (last 2021). Webpage.
Research interests: Syndromology, whole-exome sequencing, whole-genome sequencing, family cancer syndromes, cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), fragmentomics
Michael R. Speicher is Professor of Human Genetics and chair of the Institute of Human Genetics at the Medical University of Graz. He studied computer science at the University of Dortmund (Germany) and medicine at the University of Essen (Germany). He conducted his clinical and scientific training in Human Genetics at the University of Heidelberg (Germany), at Yale University (New Haven, USA), and the University of Munich (Germany). For many years, he studied chromosome structure and morphology using various molecular cytogenetic approaches and mechanisms of chromosomal instability. His more recent research focuses on rare diseases (syndromology), hereditary tumor syndromes, and the field of “liquid biopsies”. Regarding liquid biopsy, his research combines wet-lab technologies (i.e., from blood collection to generation of sequencing libraries, including the establishment of quality standards) and computational methods (bioinformatics and machine learning) with a focus on the emerging area of “fragmentomics”, i.e., the study of structural properties of plasma DNA fragments. Another interest is within precision medicine, i.e., translating complex genomic data into therapy recommendations. Webpage.